Advances in Insulin Pump Infusion Sets Symposium Report

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

  • Jennifer Y. Zhang
  • Trisha Shang
  • Sarnath Chattaraj
  • Ohad Cohen
  • Matthias Heschel
  • Robert A. Vigersky
  • Lutz Heinemann
  • Nørgaard, Kirsten
  • Svensson, Jannet
  • Bruce Buckingham
  • David C. Klonoff

Continuous subcutaneous insulin infusion (CSII) is becoming increasingly used for achieving target glycemic control as well as providing flexibility in lifestyle. In a widely used version of CSII, the insulin pump itself is attached to one end of an insulin infusion set (IIS), which delivers insulin via a thin flexible plastic tube to the patient’s body via a cannula or needle that is inserted under the skin at the other end of the IIS. Despite the increased use of CSII by patients with diabetes, there have been few recent advances in IIS technology, especially when compared to the many recent advances made in insulin pump technology and in insulin pharmacokinetics. To discuss recent developments in, and future plans for IIS development, Diabetes Technology Society virtually hosted the Advances in Insulin Pump Infusion Sets Symposium on December 1, 2020. This symposium featured experts in the field of IISs, including representatives from Medtronic and ConvaTec (which are two manufacturers that are currently developing IISs), Stanford University, Steno Diabetes Center Copenhagen, and Science Consulting in Diabetes. The webinar’s six speakers covered (1) patient burden, (2) extended wear technology, and (3) future directions in IIS development.

OriginalsprogEngelsk
TidsskriftJournal of Diabetes Science and Technology
Vol/bind15
Udgave nummer3
Sider (fra-til)705-709
Antal sider5
ISSN1932-2968
DOI
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JYZ and TS have nothing to disclose. SC is an employee of Medtronic. OC is an employee of Medtronic. MH is an employee of Convatec Infusion Care (Unomedical A/S). RAV is a full-time employee of Medtronic Diabetes. LH is a partner of Profil Institut für Stoffwechselforschung in Neuss, Germany. He is a member of advisory boards for Roche Diagnostics, Zense, and Medtronic. He is also on the Board of Directors for Lifecare. KN is a shareholder in Novo Nordisk, has received research support from Novo Nordisk, Roche Diagnostics, Rubin Medical, Sanofi, Zealand Pharma, Novo Nordisk, and Dexcom, and has served on advisory panels for Medtronic, Abbott, and Novo Nordisk. JS serves as an adviser to Medtronic, Janssen, and Novo Nordisk. She owns shares in Novo Nordisk, and has received fees for speaking on behalf of Medtronic, Sanofi, Novo Nordisk, and Bayer AG. BB is on medical advisory boards for Convatec and Medtronic. BB receives research support from the NIH, Medtronic, Insulet, Tandem, Beta Bionics, and Dexcom. DCK is a consultant to EOFlow, Fractyl, Lifecare, Novo Nordisk, Samsung, and Thirdwayv.

Funding Information:
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Medtronic provided grant support for the meeting and publication of this article.

Publisher Copyright:
© 2021 Diabetes Technology Society.

Links

ID: 301140385